Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease*
- 15 September 1996
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacology & Therapeutics
- Vol. 60 (3), 276-282
- https://doi.org/10.1016/s0009-9236(96)90054-5
Abstract
To study the pharmacokinetics and pharmacodynamics of intravenously administered arecoline in subjects with Alzheimer's disease. Plasma arecoline concentrations were measured during and after high-dose (i.e., 5 mg intravenously over 30 minutes) and up to 2 weeks of continuous multiple-dose steady-state intravenous infusions of arecoline in 15 subjects with mild to moderate Alzheimer's disease. During multiple-dose infusions, the dose of arecoline was escalated from 0.5 to 40 mg/day. Psychometric tests were administered at baseline and every other dose to determine an "optimal dose" for each subject. This dose then was administered for 1 week using a randomized, placebo-controlled, double blind, crossover design. Plasma drug concentrations were measured by GC-MS. The optimal dose of arecoline varied fourfold across subjects (4 mg/day, n = 6; 16 mg/day, n = 3) with mean plasma half-lives of 0.95 +/- 0.54 and 9.3 +/- 4.5 (SD) minutes. Clearance and volume of distribution were 13.6 +/- 5.8 L/min and 205 +/- 170 (SD) L, respectively. At the dose that optimized memory, the mean plasma level was 0.31 +/- 0.14 (SD) ng/ml, and it predicted the optimal dose in all subjects. Because optimal dose variation is due to differing plasma kinetics, the plasma arecoline level measured at a single infusion rate can be used to choose the optimal dose for memory enhancement in patients with Alzheimer's disease.Keywords
This publication has 30 references indexed in Scilit:
- Multiple-Dose Arecoline Infusions in Alzheimer's DiseaseArchives of General Psychiatry, 1988
- No response to high‐dose muscarinic agonist therapy in Alzheimer's diseaseNeurology, 1988
- Intraventricular bethanechol infusion for Alzheimer's diseaseNeurology, 1988
- Induction of depression with oxotremorine in patients with Alzheimer's diseaseAmerican Journal of Psychiatry, 1987
- Cell Loss from the Nucleus Basalis of Meynert in Alzheimer's DiseaseCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1986
- Muscarinic Agonist Therapy of Alzheimer's DiseaseArchives of Neurology, 1986
- Memory impairments following basal forebrain lesionsBrain Research, 1985
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the ratPharmacology Biochemistry and Behavior, 1983
- Human Memory and the Cholinergic SystemArchives of Neurology, 1974